Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Innoviva (INVA) Capital Expenditures (2016 - 2026)

Innoviva filings provide 13 years of Capital Expenditures readings, the most recent being $1.1 million for Q3 2025.

On a quarterly basis, Capital Expenditures rose 315.19% to $1.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.4 million, a 162.45% increase, with the full-year FY2025 number at $1.1 million, up 318.89% from a year prior.
Capital Expenditures hit $1.1 million in Q3 2025 for Innoviva, up from $270000.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $1.1 million in Q3 2025 to a low of $9000.0 in Q1 2022.
Median Capital Expenditures over the past 4 years was $33000.0 (2022), compared with a mean of $248428.6.
Biggest five-year swings in Capital Expenditures: surged 687.88% in 2023 and later grew 3.85% in 2024.
Innoviva's Capital Expenditures stood at $33000.0 in 2022, then surged by 687.88% to $260000.0 in 2023, then grew by 3.85% to $270000.0 in 2024, then surged by 315.19% to $1.1 million in 2025.
The last three reported values for Capital Expenditures were $1.1 million (Q3 2025), $270000.0 (Q3 2024), and $260000.0 (Q3 2023) per Business Quant data.